使用生物仿制药可节省大量医疗费用,这些费用可再投资于持续创新:意大利一家医疗保健公司的消费分析。

IF 2 Q3 HEALTH POLICY & SERVICES Journal of Cancer Policy Pub Date : 2024-03-18 DOI:10.1016/j.jcpo.2024.100473
Francesco Ferrara , Maurizio Capuozzo , Roberto Langella , Ugo Trama , Eduardo Nava , Andrea Zovi
{"title":"使用生物仿制药可节省大量医疗费用,这些费用可再投资于持续创新:意大利一家医疗保健公司的消费分析。","authors":"Francesco Ferrara ,&nbsp;Maurizio Capuozzo ,&nbsp;Roberto Langella ,&nbsp;Ugo Trama ,&nbsp;Eduardo Nava ,&nbsp;Andrea Zovi","doi":"10.1016/j.jcpo.2024.100473","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Biosimilar drugs offer an opportunity for all global healthcare systems because they provide significant cost savings while ensuring equal efficacy and safety in the treatment of chronic diseases. These savings can be allocated to support ongoing innovation.</p></div><div><h3>Methods</h3><p>An analysis of the usage of major biosimilar drugs across various therapeutic areas has been conducted within an Italian healthcare company serving a population of over one million. Data on consumption, expenditure, and the number of treated patients has been extracted from the company's databases. Finally, a comparison with the year 2021 has been performed to determine if biosimilar drug usage increased in 2022.</p></div><div><h3>Results</h3><p>In 2022, the data reveals that a substantial portion of the analysed active ingredients are being used as biosimilar drugs, except in a few residual cases. However, among the most consumed drugs, resistance still exists in the case of Adalimumab and Etanercept, for which expenditure on originator drugs exceeds 2 million euros.</p></div><div><h3>Conclusion</h3><p>The 2022–2021 comparison highlights the increasing use of biosimilar drugs. This data is encouraging and suggests that in the coming months, we may achieve total utilization, which would be to the benefit of the National Health System (NHS) and the citizens who can rely on an efficient and sustainable healthcare policy that is continually improving.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100473"},"PeriodicalIF":2.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company\",\"authors\":\"Francesco Ferrara ,&nbsp;Maurizio Capuozzo ,&nbsp;Roberto Langella ,&nbsp;Ugo Trama ,&nbsp;Eduardo Nava ,&nbsp;Andrea Zovi\",\"doi\":\"10.1016/j.jcpo.2024.100473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Biosimilar drugs offer an opportunity for all global healthcare systems because they provide significant cost savings while ensuring equal efficacy and safety in the treatment of chronic diseases. These savings can be allocated to support ongoing innovation.</p></div><div><h3>Methods</h3><p>An analysis of the usage of major biosimilar drugs across various therapeutic areas has been conducted within an Italian healthcare company serving a population of over one million. Data on consumption, expenditure, and the number of treated patients has been extracted from the company's databases. Finally, a comparison with the year 2021 has been performed to determine if biosimilar drug usage increased in 2022.</p></div><div><h3>Results</h3><p>In 2022, the data reveals that a substantial portion of the analysed active ingredients are being used as biosimilar drugs, except in a few residual cases. However, among the most consumed drugs, resistance still exists in the case of Adalimumab and Etanercept, for which expenditure on originator drugs exceeds 2 million euros.</p></div><div><h3>Conclusion</h3><p>The 2022–2021 comparison highlights the increasing use of biosimilar drugs. This data is encouraging and suggests that in the coming months, we may achieve total utilization, which would be to the benefit of the National Health System (NHS) and the citizens who can rely on an efficient and sustainable healthcare policy that is continually improving.</p></div>\",\"PeriodicalId\":38212,\"journal\":{\"name\":\"Journal of Cancer Policy\",\"volume\":\"40 \",\"pages\":\"Article 100473\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213538324000079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538324000079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:生物类似药为全球所有医疗保健系统提供了机遇,因为它们在确保治疗慢性疾病的同等疗效和安全性的同时,还能节省大量成本。这些节省下来的费用可用于支持持续创新:方法:在一家服务人口超过 100 万的意大利医疗保健公司内,对各治疗领域主要生物类似药的使用情况进行了分析。从该公司的数据库中提取了有关消费、支出和治疗患者人数的数据。最后,与 2021 年进行了比较,以确定 2022 年生物类似药的使用量是否有所增加:结果:数据显示,2022 年,除少数残留病例外,大部分被分析的活性成分都被用作生物类似药。然而,在消费量最大的药物中,阿达木单抗(Adalimumab)和依那西普(Etanercept)仍然存在抗药性,这两种药物的原研药支出超过了 200 万欧元:2022-2021 年的对比显示,生物仿制药的使用量在不断增加。这一数据令人鼓舞,表明在未来几个月内,我们可能会实现全部使用,这将有利于国家卫生系统(NHS)和公民,他们可以依赖于不断改进的高效、可持续的医疗保健政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company

Background

Biosimilar drugs offer an opportunity for all global healthcare systems because they provide significant cost savings while ensuring equal efficacy and safety in the treatment of chronic diseases. These savings can be allocated to support ongoing innovation.

Methods

An analysis of the usage of major biosimilar drugs across various therapeutic areas has been conducted within an Italian healthcare company serving a population of over one million. Data on consumption, expenditure, and the number of treated patients has been extracted from the company's databases. Finally, a comparison with the year 2021 has been performed to determine if biosimilar drug usage increased in 2022.

Results

In 2022, the data reveals that a substantial portion of the analysed active ingredients are being used as biosimilar drugs, except in a few residual cases. However, among the most consumed drugs, resistance still exists in the case of Adalimumab and Etanercept, for which expenditure on originator drugs exceeds 2 million euros.

Conclusion

The 2022–2021 comparison highlights the increasing use of biosimilar drugs. This data is encouraging and suggests that in the coming months, we may achieve total utilization, which would be to the benefit of the National Health System (NHS) and the citizens who can rely on an efficient and sustainable healthcare policy that is continually improving.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
期刊最新文献
Corrigendum to "Cancer research funding in South Asia" [J. Cancer Policy 41 (2024) 100489]. Utilisation Patterns of Radiotherapy Among Older Patients: Insights from Portuguese National Cancer Registry Data. Time in the U.S. and colorectal cancer screening adherence among diverse immigrants Rapid diagnostic pathways for prostate cancer: A realist synthesis Overcoming barriers of cervical cancer elimination in India: A practice to policy level advocacy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1